{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:19:44Z","timestamp":1790263184584,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ebiom.2020.102779","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T17:12:32Z","timestamp":1589217152000},"page":"102779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)"],"prefix":"10.1016","volume":"55","author":[{"given":"Rosa","family":"De Miguel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rial-Crestelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Dominguez-Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Montejano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Esteban-Cantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Aranguren-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Stella-Ascariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otilia","family":"Bisbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bermejo-Plaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Garcia-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Alejos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asunci\u00f3n","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Santacreu-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julen","family":"Cadi\u00f1anos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mayoral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Miguel","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz","family":"Martin-Carbonero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2020.102779_bib0001","unstructured":"EACS Guidelines version 10.0, November 2019. 2019;(November)."},{"key":"10.1016\/j.ebiom.2020.102779_bib0002","article-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV","year":"2018","journal-title":"Dep Heal Hum Serv"},{"key":"10.1016\/j.ebiom.2020.102779_bib0003","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and Safety of Switching to Dolutegravir\/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide\u2013Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized","author":"van Wyk","year":"2020","journal-title":"Non-inf. Clin Infect Dis."},{"key":"10.1016\/j.ebiom.2020.102779_bib0004","article-title":"Residual HIV-1 RNA, HIV-1 DNA, and Drug Plasma Cmin in Dual DTG+3TC","author":"Charpentier","year":"2019","journal-title":"ANRS 167 Lamidol. CROI 2019"},{"issue":"3","key":"10.1016\/j.ebiom.2020.102779_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ofid\/ofz056","article-title":"No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial","volume":"6","author":"Li","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.ebiom.2020.102779_bib0006","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"Paton","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ebiom.2020.102779_bib0007","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/S2352-3018(16)30011-X","article-title":"Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study","volume":"3","author":"La Rosa","year":"2016","journal-title":"lancet HIV."},{"issue":"9883","key":"10.1016\/j.ebiom.2020.102779_bib0008","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","article-title":"Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND","volume":"381","author":"Study Group","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ebiom.2020.102779_bib0009","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3018(17)30069-3","article-title":"Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286\/MOBIDIP): a multicentre, randomised, parallel, open-la","volume":"4","author":"Ciaffi","year":"2017","journal-title":"Lancet HIV"},{"issue":"4","key":"10.1016\/j.ebiom.2020.102779_bib0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jac\/dkq544","article-title":"Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia","volume":"66","author":"Wirden","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"October 2017","key":"10.1016\/j.ebiom.2020.102779_bib0011","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jviromet.2017.10.016","article-title":"Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy","volume":"251","author":"Allavena","year":"2018","journal-title":"J Virol Methods"},{"issue":"9","key":"10.1016\/j.ebiom.2020.102779_bib0012","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-1293.2012.01002.x","article-title":"Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication","volume":"13","author":"Delaugerre","year":"2012","journal-title":"HIV Med"},{"issue":"11","key":"10.1016\/j.ebiom.2020.102779_bib0013","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3018(18)30177-2","article-title":"Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study","volume":"5","author":"Inzaule","year":"2018","journal-title":"Lancet HIV"},{"issue":"6","key":"10.1016\/j.ebiom.2020.102779_bib0014","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1128\/JCM.00030-16","article-title":"Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation","volume":"54","author":"Dauwe","year":"2016","journal-title":"Caliendo AM, editor. J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.ebiom.2020.102779_bib0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2020.102779_bib0016","series-title":"17th European AIDS Conference","article-title":"Prevalence and factors associated to the detection (population and next generation sequencing) of archived 3TC resistance mutations in aviremic HIV-infected adults (GEN- PRO)","author":"Dom\u00ednguez-Dom\u00ednguez","year":"2019"},{"issue":"1","key":"10.1016\/j.ebiom.2020.102779_bib0017","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jac\/dkx366","article-title":"No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir","volume":"73","author":"Perrier","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.ebiom.2020.102779_bib0018","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/bioinformatics\/btr026","article-title":"Quality control and preprocessing of metagenomic datasets","volume":"27","author":"Schmieder","year":"2011","journal-title":"Bioinformatics"},{"issue":"21","key":"10.1016\/j.ebiom.2020.102779_bib0019","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/bioinformatics\/btr507","article-title":"Fast length adjustment of short reads to improve genome assemblies","volume":"27","author":"Mago\u010d","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ebiom.2020.102779_bib0020","article-title":"Switching To DTG-3TC Fixed-Dose Combination (Fdc) Is Non-Inferior To Continuing a Taf-Based Regimen in Maintaining Virologic Suppression Through 48 Weeks (Tango Study)","author":"Van","year":"2019","journal-title":"IAS 2019"},{"key":"10.1016\/j.ebiom.2020.102779_bib0021","article-title":"Dual regimen with dolutegravir and lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance DOLULAM study","author":"Reynes","year":"2017","journal-title":"IAS 2017"},{"issue":"10","key":"10.1016\/j.ebiom.2020.102779_bib0022","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkx233","article-title":"HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir\u202f+\u202flamivudine in the maintenance DOLULAM pilot study","volume":"72","author":"Charpentier","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ebiom.2020.102779_bib0023","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12688\/f1000research.15995.2","article-title":"Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis","volume":"7","author":"Wandeler","year":"2019","journal-title":"F1000Research"},{"issue":"6","key":"10.1016\/j.ebiom.2020.102779_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.ebiom.2020.102779_bib0025","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jac\/dkz009","article-title":"Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice","volume":"74","author":"Baldin","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ebiom.2020.102779_bib0026","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/430709","article-title":"Antiviral Activity of Lamivudine in Salvage Therapy for Multidrug\u2010Resistant HIV\u20101 Infection","volume":"41","author":"Campbell","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ebiom.2020.102779_bib0027","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.aids.0000218542.08845.b2","article-title":"Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study)","volume":"20","author":"Castagna","year":"2006","journal-title":"Aids"},{"issue":"1","key":"10.1016\/j.ebiom.2020.102779_bib0028","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1586\/14787210.2.1.147","article-title":"The impact of the M184V substitution on drug resistance and viral fitness","volume":"2","author":"Wainberg","year":"2004","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"15","key":"10.1016\/j.ebiom.2020.102779_bib0029","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1097\/QAD.0000000000001191","article-title":"The M184I\/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir","volume":"30","author":"Oliveira","year":"2016","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.ebiom.2020.102779_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open forum Infect Dis"}],"updated-by":[{"DOI":"10.1016\/j.ebiom.2023.104486","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000}}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396420301547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396420301547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T01:10:46Z","timestamp":1715044246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396420301547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":30,"alternative-id":["S2352396420301547"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2020.102779","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ebiom.2023.104486","asserted-by":"object"}]},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2020.102779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102779"}}